Description
Tirzepatide (Research-Grade Peptide)
Dual incretin agonist (GIP/GLP-1) — for laboratory research only
Product Overview
Tirzepatide is a synthetic peptide engineered to act as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP)
receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-incretin mechanism has been extensively studied in
preclinical and clinical research for its effects on glycemic regulation, body-weight reduction, and cardiometabolic risk
factors. Supplied as a high-purity lyophilized powder, this material is intended strictly for laboratory research use and is
not approved for human or veterinary administration.
Research Highlights
- Dual-Incretin Mechanism: Tirzepatide simultaneously activates GIP and GLP-1 receptors, enhancing insulin secretion,suppressing glucagon, and influencing appetite and energy balance in metabolic research models.
NEJM (2021),
Cell Metabolism - Type 2 Diabetes (SURPASS Program): Across multiple Phase 3 trials, tirzepatide demonstrated superior HbA1creductions and body-weight loss compared with placebo and active comparators, supporting once-weekly dosing regimens in advanced research.
NEJM (SURPASS-2) - Obesity Research (SURMOUNT Trials): In adults with obesity or overweight without diabetes, tirzepatide achievedmean body-weight reductions of up to ~22.5% over 72 weeks at the highest studied doses.
NEJM (2022) - Cardiometabolic Effects: Research has shown improvements in blood pressure, lipid profiles, and insulin sensitivity,highlighting tirzepatide’s broad metabolic impact under investigation.
The Lancet Diabetes & Endocrinology
Product Details & Handling
- Synonyms: Tirzepatide; LY3298176
- Form: Lyophilized powder, supplied in sterile vials
- Purity: ≥ 98% (Certificate of Analysis provided)
- Storage: Store at –20 °C; protect from light and moisture
- Handling: For use only in controlled laboratory environments with appropriate PPE; consult SDS for safety guidance
Legal Disclaimer
This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
Tirzepatide is an FDA-approved drug for specific prescription uses; however, this material is sold solely as a
research chemical and is not labeled or authorized for medical use.
Windy City Peptide does not provide medical advice or support related to human use.
GLP-2 Peptide for Research Use Only
GLP-2 (Glucagon-Like Peptide-2) is a naturally occurring peptide hormone derived from proglucagon and studied extensively in gastrointestinal and metabolic research models. In laboratory environments, GLP-2 is evaluated for its influence on intestinal mucosal growth, epithelial integrity, and nutrient transport mechanisms.
Windy City Peptides provides COA-verified GLP-2 manufactured under controlled laboratory standards to support reproducibility and experimental consistency.